Martin Moxham

Martin Moxham is a retired professional with a 31-year career in drug development and regulatory affairs. They held significant roles at organizations such as Clinical Network Services (CNS) and Scendea, where they provided expertise on pharmaceutical product development and regulatory strategies. Moxham’s earlier experience includes positions at companies like Akos International Consultancy Ltd, SmithKline Beecham, and Merck Generics, contributing to various aspects of regulatory submissions and project management. They earned a PhD in Biochemical Pharmacology from Imperial College London and a BSc in Biochemistry (Toxicology) from the University of Surrey, also attaining a Postgraduate Diploma in Computer Science from the University of Hertfordshire.